Register for our free email digests:
Latest From Fedora Pharmaceuticals Inc.
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
Point-of-care diagnostics are back in favor with investors who believe market forces and technological advances are finally converging in ways that invite success and this time, they may be right. Profiles of GeneWEAVE, HiberGene, Spectromics, and Xagenic.
A solution to global antibiotics resistance will need co-ordination, focused drug innovation and the selective use of new medicines, in a manner not unlike that which turned HIV from a terminal illness into a chronic condition, participants at the Pharma Summit 2015 are told.
In an interview at the J.P. Morgan meeting, Roche R&D and partnering execs John Reed and Sophie Kornowski-Bonnet review progress and aspirations in new therapeutic areas like ophthalmology, antimicrobials and CNS diseases.
- Medical Devices
- Therapeutic Areas
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- Electromed Inc.
- Senior Management
Kathleen Skarvan, CEO
Jeremy T Brock, CFO
John Kowalczyk, VP, Sales
- Contact Info
Phone: (952) 758-9299
500 6th Ave NW
New Prague, MN 56071
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.